MX2017016183A - Vacuna de adn que dirige vegfr-2 para terapia de combinacion. - Google Patents
Vacuna de adn que dirige vegfr-2 para terapia de combinacion.Info
- Publication number
- MX2017016183A MX2017016183A MX2017016183A MX2017016183A MX2017016183A MX 2017016183 A MX2017016183 A MX 2017016183A MX 2017016183 A MX2017016183 A MX 2017016183A MX 2017016183 A MX2017016183 A MX 2017016183A MX 2017016183 A MX2017016183 A MX 2017016183A
- Authority
- MX
- Mexico
- Prior art keywords
- vegfr
- salmonella
- copy
- combination therapy
- dna molecule
- Prior art date
Links
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 title 1
- 238000002648 combination therapy Methods 0.000 title 1
- 230000008685 targeting Effects 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 108020004414 DNA Proteins 0.000 abstract 3
- 102000053602 DNA Human genes 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 241000607142 Salmonella Species 0.000 abstract 3
- 230000002238 attenuated effect Effects 0.000 abstract 3
- 108091008605 VEGF receptors Proteins 0.000 abstract 2
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
La presente invención se refiere a una cepa atenuada de Salmonella que comprende por lo menos una copia de una molécula de ADN que comprende un casete de expresión que codifica una proteína del receptor de VEGF, para uso en el tratamiento de cáncer, en donde el tratamiento comprende adicionalmente la administración de por lo menos un agente anticanceroso adicional. La presente invención adicionalmente se refiere a una composición farmacéutica que comprende una cepa atenuada de Salmonella que comprende por lo menos una copia de una molécula de ADN que comprende un casete de expresión que codifica una proteína del receptor de VEGF, en donde la composición farmacéutica comprende adicionalmente por lo menos una cepa atenuada adicional de Salmonella que comprende por lo menos una copia de una molécula de ADN adicional que comprende un casete de expresión adicional que codifica un antígeno de tumor o un antígeno de estroma de tumor.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001803 | 2015-06-18 | ||
| PCT/EP2016/001004 WO2016202459A1 (en) | 2015-06-18 | 2016-06-16 | Vegfr-2 targeting dna vaccine for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017016183A true MX2017016183A (es) | 2018-06-19 |
Family
ID=53476620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016183A MX2017016183A (es) | 2015-06-18 | 2016-06-16 | Vacuna de adn que dirige vegfr-2 para terapia de combinacion. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US10905752B2 (es) |
| EP (2) | EP3626262A1 (es) |
| JP (1) | JP6947649B2 (es) |
| KR (1) | KR20180037948A (es) |
| CN (1) | CN107995868B (es) |
| AU (1) | AU2016278588B2 (es) |
| BR (1) | BR112017027378A2 (es) |
| CA (1) | CA2989247C (es) |
| DK (1) | DK3310379T3 (es) |
| ES (1) | ES2760699T3 (es) |
| HK (1) | HK1252435A1 (es) |
| HU (1) | HUE046631T2 (es) |
| IL (1) | IL256076A (es) |
| LT (1) | LT3310379T (es) |
| MX (1) | MX2017016183A (es) |
| PL (1) | PL3310379T3 (es) |
| RU (1) | RU2018101722A (es) |
| SI (1) | SI3310379T1 (es) |
| WO (1) | WO2016202459A1 (es) |
| ZA (1) | ZA201708439B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017353432A1 (en) * | 2016-11-04 | 2019-04-18 | Vaximm Ag | WT1 targeting DNA vaccine for combination therapy |
| US10980868B2 (en) * | 2017-02-17 | 2021-04-20 | Vaximm Ag | VEGFR-2 targeting immunotherapy approach |
| KR20190125481A (ko) * | 2017-03-17 | 2019-11-06 | 백심 아게 | 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신 |
| EP3846844A1 (en) * | 2018-09-05 | 2021-07-14 | Vaximm AG | Neoantigen targeting dna vaccine for combination therapy |
| JP2023510770A (ja) * | 2020-01-13 | 2023-03-15 | バクシム アクチェンゲゼルシャフト | 抗生剤と組み合わせた、サルモネラベースのｄｎａワクチン |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094410B2 (en) | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| LT2794849T (lt) | 2011-12-22 | 2017-12-11 | Vaximm Ag | Didelio produktyvumo susilpnintų salmonella padermių gamybos būdas |
| KR102090612B1 (ko) * | 2012-07-05 | 2020-03-19 | 백심 아게 | 췌장암 환자용 dna 백신 |
| AU2013318338B2 (en) * | 2012-09-21 | 2017-05-25 | Intensity Therapeutics, Inc | Method of treating cancer |
| BR112015018989B1 (pt) * | 2013-02-22 | 2023-11-14 | Curevac Ag | Combinação de vacina/inibidor da via de pd-1, inibidor da via de pd-1 e vacina de rna |
| CA2910213A1 (en) * | 2013-04-25 | 2014-10-30 | Vaximm Ag | Salmonella-based vectors for cancer immunotherapy targeting wilms' tumor gene wt1 |
| HUE045567T2 (hu) * | 2013-12-18 | 2020-01-28 | Vaximm Gmbh | MSLN-t célzó DNS vakcina rák immunterápiához |
-
2016
- 2016-06-16 HU HUE16736381A patent/HUE046631T2/hu unknown
- 2016-06-16 PL PL16736381T patent/PL3310379T3/pl unknown
- 2016-06-16 KR KR1020187001398A patent/KR20180037948A/ko not_active Application Discontinuation
- 2016-06-16 AU AU2016278588A patent/AU2016278588B2/en active Active
- 2016-06-16 RU RU2018101722A patent/RU2018101722A/ru not_active Application Discontinuation
- 2016-06-16 SI SI201630549T patent/SI3310379T1/sl unknown
- 2016-06-16 CN CN201680035593.2A patent/CN107995868B/zh active Active
- 2016-06-16 BR BR112017027378-0A patent/BR112017027378A2/pt not_active Application Discontinuation
- 2016-06-16 CA CA2989247A patent/CA2989247C/en active Active
- 2016-06-16 EP EP19205420.3A patent/EP3626262A1/en active Pending
- 2016-06-16 LT LTEP16736381.1T patent/LT3310379T/lt unknown
- 2016-06-16 US US15/737,659 patent/US10905752B2/en active Active
- 2016-06-16 ES ES16736381T patent/ES2760699T3/es active Active
- 2016-06-16 WO PCT/EP2016/001004 patent/WO2016202459A1/en active Application Filing
- 2016-06-16 EP EP16736381.1A patent/EP3310379B1/en active Active
- 2016-06-16 JP JP2017565248A patent/JP6947649B2/ja active Active
- 2016-06-16 DK DK16736381.1T patent/DK3310379T3/da active
- 2016-06-16 MX MX2017016183A patent/MX2017016183A/es unknown
-
2017
- 2017-12-04 IL IL256076A patent/IL256076A/en unknown
- 2017-12-12 ZA ZA2017/08439A patent/ZA201708439B/en unknown
-
2018
- 2018-09-12 HK HK18111736.6A patent/HK1252435A1/zh unknown
-
2020
- 2020-11-30 US US17/107,203 patent/US20210077605A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180037948A (ko) | 2018-04-13 |
| LT3310379T (lt) | 2019-12-27 |
| JP6947649B2 (ja) | 2021-10-13 |
| SI3310379T1 (sl) | 2020-02-28 |
| AU2016278588A1 (en) | 2017-12-21 |
| CA2989247C (en) | 2023-10-17 |
| US20210077605A1 (en) | 2021-03-18 |
| ES2760699T3 (es) | 2020-05-14 |
| EP3310379B1 (en) | 2019-11-06 |
| WO2016202459A1 (en) | 2016-12-22 |
| PL3310379T3 (pl) | 2020-03-31 |
| RU2018101722A3 (es) | 2019-12-10 |
| CN107995868A (zh) | 2018-05-04 |
| US10905752B2 (en) | 2021-02-02 |
| JP2018517419A (ja) | 2018-07-05 |
| DK3310379T3 (da) | 2019-12-16 |
| EP3626262A1 (en) | 2020-03-25 |
| AU2016278588B2 (en) | 2022-03-31 |
| RU2018101722A (ru) | 2019-07-18 |
| EP3310379A1 (en) | 2018-04-25 |
| IL256076A (en) | 2018-01-31 |
| US20180250345A1 (en) | 2018-09-06 |
| CA2989247A1 (en) | 2016-12-22 |
| HUE046631T2 (hu) | 2020-03-30 |
| BR112017027378A2 (pt) | 2018-08-28 |
| CN107995868B (zh) | 2021-07-13 |
| HK1252435A1 (zh) | 2019-05-24 |
| ZA201708439B (en) | 2021-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124791T1 (el) | Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων | |
| MX2017016183A (es) | Vacuna de adn que dirige vegfr-2 para terapia de combinacion. | |
| PH12019500270A1 (en) | Combination therapy for cancer | |
| MX2020005651A (es) | Receptor de antigeno quimerico dirigido a bcma y usos del mismo. | |
| MX2021008224A (es) | Combinacion de vacunacion e inhibicion de la trayectoria pd-1. | |
| TR201900649T4 (tr) | Oküler hastalıkların tedavisi için mrna tedavisi. | |
| EA201890272A1 (ru) | Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака | |
| EA201691023A1 (ru) | Пептидомиметические соединения и их конъюгаты антитела с лекарственным средством | |
| PH12017500023A1 (en) | Targeted conjugates and particles and formulations thereof | |
| MX2017007321A (es) | Terapias de combinacion. | |
| MX2021008113A (es) | Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma. | |
| EA201790674A1 (ru) | Индуцирующий цитотоксичность терапевтический агент | |
| MX2017003246A (es) | Macropinocitosis de anticuerpos anti-cd46 humanos y agentes terapeuticos dirigidos contra el cancer. | |
| MX2016007851A (es) | Compuestos peptidomimeticos y conjugados anticuerpo-farmaco de estos. | |
| MX2017016253A (es) | Anticuerpos para cd40. | |
| BR112016023025A2 (pt) | direcionamento de câncer de mama her2+ resistente a trastuzumab com uma nanopartícula de direcionamento de her3 | |
| BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
| MX359315B (es) | Vacuna de adn para usarse en pacientes con cancer pancreatico. | |
| MX2016009284A (es) | Construcciones dirigidas a receptor y sus usos. | |
| BR112017014793A2 (pt) | regime de dosagem para antagonistas de madcam | |
| CY1122508T1 (el) | Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου | |
| HK1232242A1 (zh) | 用於癌症靶向治療的包含基於重組血紅蛋白蛋白質或亞基的治療劑的藥物組合物 | |
| BR112016023011A2 (pt) | tratamento de câncer gástrico | |
| EA201792314A1 (ru) | Фармацевтическая комбинация эверолимуса и дактолисиба | |
| MX2019011026A (es) | Nueva vacuna de adn dirigida a pd-l1 para inmunoterapia de cancer. |